The relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation
This study examines the relationship between obesity and the increase in serum 25(OH)D levels in response to vitamin D supplementation among adults with baseline serum 25(OH)D levels <50 nmol/L. This study revealed that the increase in serum 25(OH)D in response to vitamin D supplementation was higher in lean subjects as compared to obese subjects.
Serum 25(OH)D is lower among obese than non-obese. This study examines the relationship between obesity and the increase in serum 25(OH)D in response to vitamin D supplementation in a large sample of adults with baseline serum 25(OH)D <50 nmol/L, relatively long average treatment duration and large average daily cholecalciferol.
The computerized database of the Clalit Health Services, which the largest nonprofit health maintenance organization in Israel, was retrospectively searched for all subjects aged ≥20 years who performed serum 25(OH)D test in 2011. Subjects with more than one test at different occasions in 2011 were identified and were included if the result of the first test was <50 nmol/L, and were treated with cholecalciferol between the first and the last test in 2011 (n = 16,540 subjects).
The mean increase in serum 25(OH)D level after treatment was 28.7 (95 % confidence interval (CI), 28.0–29.4) nmol/L, 23.6 (23.0–24.2) nmol/L, and 20.1 (19.6–20.6) nmol/L in subject with BMI of <25, 25–29.9, and ≥30 kg/m2, respectively (P < 0.001). The results were similar after adjustment for the potential confounders. Similarly, the proportion of subjects who achieved serum 25(OH)D ≥ 50 nmol/L after treatment was inversely associated with BMI; 65.1, 58.3, and 49.1 % for BMI of <25, 25–29.9, and ≥ 30 kg/m2, respectively. Compared to BMI of ≥30 kg/m2, the adjusted odds ratio for achieving levels of ≥50 nmol/L were 2.12 (95 % CI, 1.94–2.31) and 1.42 (1.31–1.54) for BMI of <25 kg/m2, and BMI of 25–29.9 kg/m2, respectively.
BMI is inversely associated with the increase in serum 25(OH)D levels in response to vitamin D supplementation.
Keywords25(OH)D BMI Cholecalciferol Obesity Response to treatment Vitamin D
- 1.Pearce SH, Cheetham TD (2010) Diagnosis and management of vitamin D deficiency. BMJ 340:142–147Google Scholar
- 6.Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W (2008) Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 168:1340–1349PubMedCrossRefGoogle Scholar
- 14.National Academy of Science, Institute of Medicine (2011) Dietary references intake for calcium and vitamin D. http://www.nap.edu/catalog.php?record_id=13050. Accessed 1 Sept 2011
- 15.Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, Kovacs CS, Mayne ST, Rosen CJ, Shapses SA (2011) The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 96:53–58PubMedCrossRefGoogle Scholar
- 18.Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, Murad MH, Weaver CM, Endocrine Society (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 96:1911–1930PubMedCrossRefGoogle Scholar